It is now a mainstream pathway for initiating therapy
Out of the current antidiabetic medications, 2.4 mg semaglutide OW is the only one approved for the treatment of MASH by FDA Phase 3 trials with tirzepatide and dual GLP-1/glucagon agonist survodutide are ongoing Many other GLP-1-based emerging medications such as cagrilintide/semaglutide, triple GLP-1/GIP/glucagon agonist retatrutide, small non-peptide GLP-1 agonist orforglipron and many others may also have a great potential to improve MASLD or MASH Based on the excellent review paper by Scott Isaacs, MD, FACP, FACE and colleagues published in Frontline Gastroenterology #mash #mafld #antidiabeticmedication #semaglutide #tirzepatide #survodutide #pioglitazone #insulin #metformin #cvcomplications To view or add a comment, sign in TL;DR microdosing psilocybin may treat diabetes *in mice A new study in the journal Pharmacological Research showed that low-dose psilocybin reduced body-weight gain, liver steatosis, hyperglycaemia, and insulin resistance without eliciting central nervous system effects
Low-dead-space syringes (sometimes called "fixed needle" or "zero dead space" syringes) minimize this waste
And she goes, that's all I'll tell you
I took a little short position in a basket of some restaurant stocks while I keep ramping up and doing more work
Acknowledgements This study was supported by a grant from the Chung Shan Medical University (CSMU-INT-101-09), Taiwan
